VKTX Viking Therapeutics Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
10:24
Sep 23
Sep 23
r/biotech_stocks
VK2735 maintenance data strengthen but don't complete thesis
Author argues the VK2735 maintenance data strengthen the bull case because less-frequent (QOW and monthly) maintenance dosing is now supported by human clinical data, with best QOW cohort retaining 97% of prior weight loss and the 17.5 mg weekly cohort reaching 21.7% mean weight loss at Week 33 without an observed plateau. The mechanism is that viable less-frequent maintenance dosing could improve convenience and adherence for an obesity drug, supporting commercial differentiation. The key catalyst is the larger VANQUISH Phase 3 trials, while the main stated risks are that maintenance is only 12 weeks, individual cohorts were small, and PK/exposure-response data are still needed.
VKTX
Viking Therapeutics
Long
1ST
—
—
21:57
Sep 22
Sep 22
3PRO TV
Viking obesity dosing maintains efficacy
Viking Therapeutics showed that reducing dosing frequency still maintains most of its weight-loss effect, a positive efficacy signal for its obesity drug. The stock surged.
VKTX
Viking Therapeutics
Long
1ST
—
—
13:00
Jun 30
Jun 30
Author names VKTX as a medium-term favorite pick when asked to choose among a group of five.
VKTX
Viking Therapeutics
Long
—
—
About VKTX Investor Commentary
Across the available history and selected sources, Buzzberg tracks VKTX (Viking Therapeutics) across 14 sources: 19 bullish vs 0 bearish calls from 19 authors. Historical directional balance: 34% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 56 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: u/r4dpere, Park Myung-seok, __con_.